Patent · US Active

Targeted sensitization of non-del(5q) malignant cells

US10682417B2 · kind B2 · utility

0Cited by

9References

12Claims

0Family size

Assignee

H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US

Inventors

Alan F. List · Tampa, US
Sheng Wei · Tampa, US

Key dates

Filing date	Apr 3, 2018
Grant date	Jun 16, 2020
Priority date	—
Expiry date	Apr 3, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Acα, or a combination thereof, and a toll like receptor-9 (TLR9) targeting ligand. The molecule can also contain lenalidomide, or an analogue or derivative thereof. Also disclosed is a composition comprising the disclosed molecule in a pharmaceutically acceptable carrier. Also disclosed is a method for treating non-del(5q) meylodysplastic syndrome (MDS) in a subject by administering to the subject a therapeutically effective amount of the disclosed pharmaceutical composition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.